Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy

Cancer Medicine

Volumn 3, Issue 4, 2014, Pages 980-987

  Fernanda Amary, M ^a,b   Ye, Hongtao ^a   Berisha, Fitim ^a   Khatri, Bhavisha ^a   Forbes, Georgina ^a   Lehovsky, Katie ^a   Frezza, Anna M ^b,c   Behjati, Sam ^d   Tarpey, Patrick ^d   Pillay, Nischalan ^a,b   Campbell, Peter J ^d   Tirabosco, Roberto ^a   Presneau, Nadège ^b   Strauss, Sandra J ^b,c   Flanagan, Adrienne M ^a,b  

^a ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Amplification; FGFR; FGFR1; FISH; Genetics; Osteosarcoma; Polysomy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; METHOTREXATE; FGFR1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CHILD; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FGFR1 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; BONE NEOPLASMS; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OSTEOSARCOMA; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929142961     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.268     Document Type: Article

References (29)

1. Link, M. P., A. M. Goorin, A. W. Miser, et al. 1986. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med. 314:1600-1606.
2. Fletcher, C. D. M. 2013. World Health Organization., International Agency for Research on Cancer. WHO classification of tumours of soft tissue and bone. 4th ed. IARC Press, Lyon, France.
3. Sandberg, A. A., and J. A. Bridge . 2003. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet. Cytogenet. 145:1-30.
4. Duhamel, L. A., H. Ye, D. Halai, et al. 2012. Frequency of mouse double minute 2 (MDM2) and mouse double minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes. Histopathology 60:357-359.
5. Hauben, E. I., S. Weeden, J. Pringle, E. A. Van Marck, and P. C. Hogendoorn . 2002. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur. J. Cancer 38:1218-1225.
6. Angstadt, A. Y., A. Motsinger-Reif, R. Thomas, et al. 2011. Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart. Genes Chromosom. Cancer 50:859-874.
7. Dalla-Torre, C. A., S. R. de Toledo, M. Yoshimoto, et al. 2007. Expression of major vault protein gene in osteosarcoma patients. J. Orthop. Res. 25:958-963.
8. Dalla-Torre, C. A., M. Yoshimoto, C. H. Lee, et al. 2006. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 6:237.
9. Man, T. K., X. Y. Lu, K. Jaeweon, et al. 2004. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4:45.
10. PosthumaDeBoer, J., M. A. Witlox, G. J. Kaspers, and B. J. van Royen . 2011. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin. Exp. Metastasis 28:493-503.
11. Sadikovic, B., P. C. Park, S. Selvarajah, and M. Zielenska . 2013. Array comparative genomic hybridization in osteosarcoma. Methods Mol. Biol. 973:227-247.
12. Rozeman, L. B., A. M. Cleton-Jansen, and P. C. Hogendoorn . 2006. Pathology of primary malignant bone and cartilage tumours. Int. Orthop. 30:437-444.
13. Guagnano, V., A. Kauffmann, S. Wohrle, et al. 2012. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2:1118-1133.
14. Amary, M. F., F. Berisha, and C. Bernardi Fdel, et al. 2007. Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma. Mod. Pathol. 20:482-496.
15. Varella-Garcia, M., J. Diebold, D. A. Eberhard, et al. 2009. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J. Clin. Pathol. 62:970-977.
16. Elbauomy Elsheikh, S., A. R. Green, and M. B. Lambros, et al. 2007. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 9:R23.
17. Turner, N., A. Pearson, R. Sharpe, et al. 2010. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70:2085-2094.
18. Luqmani, Y. A., M. Graham, and R. C. Coombes . 1992. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br. J. Cancer 66:273-280.
19. Goke, F., A. Franzen, R. Menon, et al. 2012. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. Chest 142:1020-1026.
20. Weiss, J., M. L. Sos, and D. Seidel, et al. 2010. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2:62ra93.
21. Dutt, A., A. H. Ramos, P. S. Hammerman, et al. 2011. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 6:e20351.
22. Heist, R. S., M. Mino-Kenudson, L. V. Sequist, et al. 2012. FGFR1 amplification in squamous cell carcinoma of the lung. J. Thorac. Oncol. 7:1775-1780.
23. Schultheis, A. M., M. Bos, and K. Schmitz, et al. 2013. Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. Mod. Pathol. 27:214-221.
24. Birrer, M. J., M. E. Johnson, K. Hao, et al. 2007. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J. Clin. Oncol. 25:2281-2287.
25. Letessier, A., F. Sircoulomb, C. Ginestier, et al. 2006. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6:245.
26. Miraoui, H., and P. J. Marie . 2010. Fibroblast growth factor receptor signaling crosstalk in skeletogenesis. Sci. Signal. 3:re9.
27. Schildhaus, H. U., L. C. Heukamp, S. Merkelbach-Bruse, et al. 2012. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod. Pathol. 25:1473-1480.
28. Hanna, W. M., J. Ruschoff, and M. Bilous, et al. 2013. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod. Pathol. 27:4-18.
29. Rosenberg, C. L. 2008. Polysomy 17 and HER-2 amplification: true, true, and unrelated. J. Clin. Oncol. 26:4856-4858.